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We readwith concern the paper byOng et al. [1] having
ourselves conducted a similar analysis of elevated serum
alanine aminotransferase (ALT) and mortality using the
same dataset, i.e. the National Health and Nutrition
Examination Survey (NHANES) III Linked Mortality
File [2]. In contrast to their analysis, we found no increase
in overall mortality with elevated ALT. Ong and col-
leagues reported an adjusted hazard ratio (HR) for over-
all mortality of 1.038 with a 95% conﬁdence interval (CI)
of 1.036–1.041. In contrast, our adjusted HR estimate for
all-cause mortality was 1.2 with a 95% CI of 0.88–1.6.
While there were diﬀerences between the two papers
in the selection of the analytical samples and in the def-
initions of elevated ALT versus what they deemed as
‘‘NAFLD”, we believe the most likely explanation for
these contrasting ﬁndings was incorrect statistical meth-
ods used by Ong and colleagues for the calculation of
variance from the complex NHANES III sample.
NHANES has always used a highly stratiﬁed sample
in order to derive health measures for the U.S. popula-
tion. As such, analyses require consideration of the com-
plex sample design in order to determine the precision
and statistical signiﬁcance of any statistic. As advised
by the NHANES III sponsor [3], when using the sample
weights the strata and primary sampling unit pairings
from the sample design should also be used in estimating
variances and testing for statistical signiﬁcance. To do
this it is necessary to use computer software packages
such as SUDAAN or Stata. Ong and colleagues re-
ported using SAS software, which does not have a pro-
cedure to properly estimate variances from complex
samples when using Cox proportional hazards regres-
sion analysis. Consequently, standard errors are under-
estimated and conﬁdence intervals are inappropriately
narrow. For example, if we had incorrectly analyzed
our data using SAS instead of SUDAAN, we would
have obtained a hazard ratio estimate of 1.192 with a
95% CI of 1.189–1.194. While our hazard ratio estimate
would remain unchanged (1.2 when rounded to one dec-
imal place), the conﬁdence interval becomes inappropri-ately small, leading to the incorrect conclusion of
statistical signiﬁcance. This problem can be easily seen
by rounding to 2 decimal places resulting in a hazard ra-
tio of 1.19 with 95% conﬁdence interval of 1.19–1.19.
Such precision exists in no medical study. We suggest
that if Ong and colleagues were to repeat their analyses
using the recommended statistical methods for variance
estimation, they would no longer ﬁnd increased overall
mortality in ‘‘NAFLD”.
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